GLP-1 Procurement Guide: Sourcing Semaglutide, Liraglutide and Tirzepatide Pens

Short answer: what you are really buying in a GLP-1 pen

Buying GLP-1 peptides is not like buying a generic tablet, because the value sits in three places a price sheet never shows: the device the patient touches, the peptide quality behind the pen, and the cold chain that keeps the product usable between factory and pharmacy shelf. A pen that arrives with an incomplete documentation pack, or a shipment that spends hours outside 2–8 °C, is not a cheaper version of the same product — it is unsellable product. Here is what to specify, and how the Artemisine GLP-1 and weight management line answers each point.

Why GLP-1 sourcing is a different procurement problem

• The molecule is small and the consequences are not. Peptide aggregation and related-substance growth are not visible through the vial wall and cannot be corrected in distribution.
• Three molecules, three clinical positions. A weekly multi-dose pen, a daily multi-dose pen and a weekly single-dose pen are different devices with different registration files.
• Every unit is cold chain. Storage is 2–8 °C before first use and the product must not be frozen — exposure happens inside the shipping container.
• Registration is a technical file, not a certificate. Peptide dossiers are assessed on assay, purity, related substances and stability.

Seven dimensions that decide whether a GLP-1 quotation is workable

1. Presentation and device

Fix the presentation before you fix the price: it drives the device, the stability file and the label. The semaglutide prefilled pen is a once-weekly multi-dose pen in 1.5 mL and 3 mL sizes — a 3 mL pen contains 9.6 mg and delivers four weekly doses of 2.4 mg, supplied with four disposable needles for single-patient use. The liraglutide prefilled pen is a once-daily 6 mg/mL pen, each holding 18 mg in 3 mL with dose steps of 0.6, 1.2, 1.8, 2.4 and 3.0 mg, packed one or three pens per box. Tirzepatide, the GIP/GLP-1 dual receptor agonist, is supplied as weekly single-dose pens from 2.5 mg to 15 mg per 0.5 mL, four pens per box. A single-dose pen and a multi-dose pen are different registration objects, and the single-dose format shortens the in-use stability story a registration file has to tell.

2. Peptide quality control

Ask how identity, assay, purity and related substances are controlled and what the limits are, then ask to see them. The Artemisine peptide line uses validated peptide assay and purity control with HPLC and LC-MS related-substance limits, tested per batch against the release standard for that product. Raw materials are inspected against pharmacopoeia monographs on incoming, in-process monitoring is applied during production, and finished products undergo full testing before release — see the Artemisine quality and GMP documentation. Obtain a current batch Certificate of Analysis before committing.

3. Cold chain

This is the dimension buyers most often under-specify. The requirement is an unbroken 2–8 °C from the cleanroom to your warehouse: validated insulated packaging, calibrated temperature data-loggers, and a receiving rule that reads the trace on arrival. Storage before first use is a refrigerator at 2–8 °C, do not freeze. After first use, the semaglutide pen may be kept below 30 °C or preferably refrigerated for up to 6 weeks, and the liraglutide pen for up to 1 month, with the cap kept on to protect from light. Put the excursion rule into the contract — reject on excursion, or quarantine pending review — because a buyer who accepts an excursion at the port has already made the quality decision for the patient.

4. Registration file

Every GLP-1 lot from Artemisine ships with COA, COPP, DMF and CTD-format dossiers. For a first-time importer the useful question is not "do you have a dossier" but "which submission does this dossier support" — a generic CTD file and a stringent-authority submission are different work products. Ask for the dossier index, the DMF listing and the stability summary together, then test them against your own market's requirements before commercial terms are discussed. Clinical reference on the Artemisine GLP-1 product pages is summarised from the WHO Model Formulary and WHO Model List of Essential Medicines — a starting point for indications and dosing, not a substitute for your national assessment.

5. Capacity and continuity

Ask for the line's real capacity and the site-level numbers behind it. Artemisine publishes sterile formulation capacity of 300 million ampoule injections per year (1–5 mL), 100 million IV infusion bottles per year and 50 million eye-drop units per year, with the injection category carrying 67 products including insulin and GLP-1 sterile formulations. Published figures let a buyer hold the supplier to them rather than to a verbal assurance.

6. Packaging and market fit

GLP-1 pens are ordered in market-specific packaging, and Artemisine supplies them with patient information leaflets and registration support alongside the device configuration. This is where a distributor's real work sits: local labelling, leaflet language, box format, and a pen the patient can actually operate. Buyers who want their own brand can specify customised formulation, packaging and documentation under the OEM and private-label service the company offers.

7. MOQ, stock and the answer you should expect

MOQ and lead time depend on the product. Artemisine states that MOQ depends on the product, that regular items are in stock for fast delivery, and that an exact quotation is issued against a named product and quantity, with inquiries answered within 24 hours. Fix the molecule, presentation, strength and destination market first, then request stock position, MOQ and a dated lead time in writing against that specification. MOQ, lead time and a current batch COA in one message is the minimum that lets you compare two manufacturers on the same basis.

Where the rest of the diabetes portfolio fits

A GLP-1 pen rarely arrives alone in a distributor's portfolio. The diabetes medicines line at the same GMP site covers the injectable insulin family at 100 IU/mL — regular, isophane protamine (NPH) and mixed protamine (biphasic 30/70) — plus insulin glargine, and the SGLT2 class in dapagliflozin 10 mg, empagliflozin 25 mg and canagliflozin 300 mg tablets. The Artemisine CGMS continuous glucose monitoring system pairs a factory-calibrated 14-day wearable sensor with a transmitter and a smartphone app, offered with OEM/ODM options including private-label app and market-specific packaging. One manufacturer means one audit cycle, one deviation process and one dossier format.

How to test a GLP-1 quotation before you sign

1. Fix the molecule, presentation, strength and pack configuration per SKU — these drive the device, the stability file and the artwork.
2. Ask for a current batch COA and the release standard in the same message as the quotation.
3. Request the dossier index, DMF listing, COPP and stability summary together, and state which submission each supports in your market.
4. Get the cold-chain evidence in writing: validated 2–8 °C packaging, calibrated data-loggers, and the excursion rule you will put into the contract.
5. Confirm MOQ, stock position and a dated lead time against your destination market and expected annual volume.
6. Plan the audit. GMP certificates, water system validation summaries, stability data and quality agreements are available, and on-site and remote audits are welcome.

What Artemisine commits to on this line

The sterile workshop passed the China GMP on-site inspection again in 2026, with cleanrooms graded A to D and a Grade A filling zone over a Grade B background, and Water for Injection produced by 3-stage reverse osmosis plus multi-effect distillation. Every commercial batch is retained until one year beyond the labelled expiry date, and no batch ships without QA batch-record review, QC results review and formal release certification. The company states that it has served over 50 countries across Asia, Africa, the Middle East, Latin America and Europe, and that it offers customised formulation, packaging and documentation for OEM and private-label projects alongside COA, HPLC, GC, DMF, dossier and export certificates. The Artemisine company profile also states that the company is independent and not affiliated with Sinopharm Group — which matters to buyers who need the manufacturing file owned by the party that signs the batch.

Send the molecule, the presentation and the destination market to the Artemisine export team, and the quotation, MOQ, lead time and documentation pack come back against that specification; inquiries are answered within 24 hours.

Frequently asked questions

Source: clinical reference summarised from the WHO Model List of Essential Medicines, World Health Organization; peptide manufacturing, cold-chain and quality facts from Artemisine GMP documentation. This guide is for buyer education only — clinical decisions must follow the locally approved product insert and national treatment guidelines.